Table 3.
Median concentrations of PGE2 and celecoxib in plasma in ng/ml based on celecoxib dose1
Population: Dose | Before (N) | After (N | After v. | P value | ||
Treatment | Treatment | Before(N) | ΔPGE2 | Celecoxib Level & ΔPGE2 | ||
200 mg twice daily | ||||||
Overall | PGE2 | 0.24(20) | 0.22(20) | -0.003(20) | 0.70 | 0.25 |
Celecoxib | 253.4(20) | |||||
Premenopausal | PGE2 | 0.42(6) | 0.33(6) | 0.008(6) | 1.0 | |
Celecoxib | 195.3(6) | |||||
Postmenopausal | PGE2 | 0.21(14) | 0.20(14) | -0.004(14) | 0.58 | |
Celecoxib | 267.5(14) | |||||
400 mg twice daily | ||||||
Overall | PGE2 | 0.29(26) | 0.21(26) | -0.016(20) | 0.72 | 0.93 |
Celecoxib | 759.8(26) | |||||
Premenopausal | PGE2 | 0.37(11) | 0.37(11) | -0.0005(11) | 0.77 | |
Celecoxib | 227.3(11) | |||||
Postmenopausal | PGE2 | 0.28(15) | 0.19(15) | -0.037 | 0.64 | |
Celecoxib | 860.6(15) |
1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE2 (was the change from before to after treatment significant) and celecoxib level & ΔPGE2 (was the celecoxib level after treatment related to the change in PGE2)